| 产品描述： | Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) |
| 靶点： |
Maytansinoids;MicrotubuleAssociated |
| 体外研究： |
Mertansine is a strong antiproliferative chemotherapeutics toward over 60 types of cancer cell lines. Mertansine (0-1 μg/mL) shows antitumor activity in malignant B16F10 melanoma cells, and inhibits tumor cell growth by inhibiting mitosis when combined with DTX. Cell Proliferation Assay Cell Line: Malignant B16F10 melanoma cells Concentration: 0, 0.01, 0.1, and 1 μg/mL Incubation Time: 4 h Result: Showed antitumor activity in malignant B16F10 melanoma cells, with an IC50 of 0.092 μg/mL. Co-delivery of DTX and DM1, both of which inhibit tumor cell growth by inhibiting mitosis, is an effective strategy to achieve a combinatorial anticancer effect. |
| 体内研究： |
Mertansine (DM1) has a low maximum-tolerated dose (MTD) of 1 mg/kg |
| 参考文献： |
1. Manu Lopus et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. 2. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8. 3. Zhong P, et al. cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. Nanotechnology. 2017 Jul 21;28(29):295103. |
| 溶解性： |
soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.354 ml |
6.772 ml |
13.545 ml |
| 5 mM |
0.271 ml |
1.354 ml |
2.709 ml |
| 10 mM |
0.135 ml |
0.677 ml |
1.354 ml |
| 50 mM |
0.027 ml |
0.135 ml |
0.271 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京